Greenstone Biosciences and Intel chase faster drug discovery as regulators back human-relevant models
Discover how Greenstone Biosciences and Intel plan to scale iPSC drug discovery, and why validation will determine the platform’s impact.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Curi Bio and Battelle commercialise human NMJ assay as GLP-ready alternative to mouse bioassay for botulinum toxin testing
Curi Bio and Battelle partner to commercialise a human NMJ assay for botulinum toxin potency testing. What this changes for NAM adoption and the mouse bioassay. Read more.
Pharma & Biotech
M&G backs bit.bio with $50m Series C to accelerate NAMs and AI-ready cell models
bit.bio raised $50M to expand its human cell programming platform for toxicology and AI model training. Find out why investors are backing NAMs now.